Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 4 stocks made the list for top value stocks in the Health Care Equipment & Supplies industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.
Why Focus on Undervalued Health Care Equipment & Supplies Stocks?
Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.
AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
What Goes Into AAII’s Value Grade?
Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.
Click the button below to learn more about A+ Investor and subscribe today.
4 Undervalued Health Care Equipment & Supplies Stocks
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Health Care Equipment & Supplies industry for Monday, May 11, 2026. Let’s take a closer look at their individual scores to see how they measure up against each other and the Health Care Equipment & Supplies industry median.
| Company | Ticker | Price/Sales | Price/Earnings | EV/EBITDA | Shareholder Yield | Price/Book Value | Price/Free Cash Flow | Value Grade |
| CONMED Corporation | CNMD | 0.83 | 20.8 | 11.9 | 1.2% | 1.09 | 10.8 | B |
| InMode Ltd. | INMD | 2.76 | 9.8 | 29.9 | 23.9% | 1.29 | 10.7 | B |
| DENTSPLY SIRONA Inc. | XRAY | 0.60 | na | 7.8 | (0.4%) | 1.67 | na | B |
| Zimmer Biomet Holdings, Inc. | ZBH | 1.93 | 21.3 | 11.9 | 3.2% | 1.26 | 17.1 | B |
The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.
The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)
Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).
As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.
CONMED Corporation’s Value Grade
Value Grade:
| Metric | Score | CNMD | Industry Median |
| Price/Sales | 28 | 0.83 | 2.75 |
| Price/Earnings | 52 | 20.8 | 26.1 |
| EV/EBITDA | 46 | 11.9 | 15.6 |
| Shareholder Yield | 35 | 1.2% | (3.2%) |
| Price/Book Value | 26 | 1.09 | 2.63 |
| Price/Free Cash Flow | 26 | 10.8 | 27.2 |
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
CONMED Corporation has a Value Score of 74, which is considered to be undervalued.
When you look at CONMED Corporation’s price-to-sales ratio at 0.83 compared to the industry median at 2.75, this company has a lower price relative to revenue compared to its peers. This could make CONMED Corporation’s stock more attractive for value investors.
CONMED Corporation’s price-earnings ratio is 20.80 compared to the industry median at 26.10. This means it has a lower share price relative to earnings compared to its peers. This could make CONMED Corporation more attractive for value investors.
Now, let’s assess CONMED Corporation’s EV/EBITDA ratio, also known as enterprise multiple. At 11.9, when compared to the industry median of 15.6, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.
Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. CONMED Corporation’s shareholder yield is higher than its industry median ratio of (3.20%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.
As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. CONMED Corporation’s price-to-book ratio is lower than its industry median ratio of 2.63. This could make CONMED Corporation more attractive to investors looking for a new addition to their portfolio.
Lastly, let’s take a look at CONMED Corporation’s price-to-free-cash-flow ratio (P/FCF), which can indicate a company’s market value relative to its operating cash flow. CONMED Corporation’s price-to-free-cash-flow ratio is lower than its industry median ratio of 27.20. This could make CONMED Corporation more attractive because the lower P/FCF ratio indicates that CONMED Corporation is undervalued. The P/FCF ratio metric can also be viewed over a long-term time frame to see if the company's cash flow to share price value is generally improving or worsening.
InMode Ltd.’s Value Grade
Value Grade:
| Metric | Score | INMD | Industry Median |
| Price/Sales | 59 | 2.76 | 2.75 |
| Price/Earnings | 16 | 9.8 | 26.1 |
| EV/EBITDA | 86 | 29.9 | 15.6 |
| Shareholder Yield | 1 | 23.9% | (3.2%) |
| Price/Book Value | 33 | 1.29 | 2.63 |
| Price/Free Cash Flow | 25 | 10.7 | 27.2 |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
InMode Ltd. has a Value Score of 71, which is considered to be undervalued.
InMode Ltd.’s price-earnings ratio is 9.8 compared to the industry median at 26.1. This means that it has a lower price relative to its earnings compared to its peers. This makes InMode Ltd. more attractive for value investors.
InMode Ltd.’s price-to-book ratio is higher than its peers. This could make InMode Ltd. less attractive for value investors when compared to the industry median at 2.63.
You can read more about InMode Ltd.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
DENTSPLY SIRONA Inc.’s Value Grade
Value Grade:
| Metric | Score | XRAY | Industry Median |
| Price/Sales | 21 | 0.60 | 2.75 |
| Price/Earnings | na | na | 26.1 |
| EV/EBITDA | 23 | 7.8 | 15.6 |
| Shareholder Yield | 52 | (0.4%) | (3.2%) |
| Price/Book Value | 44 | 1.67 | 2.63 |
| Price/Free Cash Flow | na | na | 27.2 |
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
DENTSPLY SIRONA Inc. has a Value Score of 75, which is considered to be undervalued.
DENTSPLY SIRONA Inc.’s price-to-book ratio is higher than its peers. This could make DENTSPLY SIRONA Inc. less attractive for value investors when compared to the industry median at 2.63.
You can read more about DENTSPLY SIRONA Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Zimmer Biomet Holdings, Inc.’s Value Grade
Value Grade:
| Metric | Score | ZBH | Industry Median |
| Price/Sales | 47 | 1.93 | 2.75 |
| Price/Earnings | 54 | 21.3 | 26.1 |
| EV/EBITDA | 46 | 11.9 | 15.6 |
| Shareholder Yield | 24 | 3.2% | (3.2%) |
| Price/Book Value | 32 | 1.26 | 2.63 |
| Price/Free Cash Flow | 45 | 17.1 | 27.2 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Zimmer Biomet Holdings, Inc. has a Value Score of 62, which is considered to be undervalued.
Zimmer Biomet Holdings, Inc.’s price-earnings ratio is 21.3 compared to the industry median at 26.1. This means that it has a lower price relative to its earnings compared to its peers. This makes Zimmer Biomet Holdings, Inc. more attractive for value investors.
Zimmer Biomet Holdings, Inc.’s price-to-book ratio is higher than its peers. This could make Zimmer Biomet Holdings, Inc. less attractive for value investors when compared to the industry median at 2.63.
You can read more about Zimmer Biomet Holdings, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Other Health Care Equipment & Supplies Stock Grades
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.
Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Health Care Equipment & Supplies stocks as well as other industrys.
Choosing Which of the 4 Best Health Care Equipment & Supplies Stocks Is Right for You
Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.
- CONMED Corporation stock has a Value Grade of B.
- InMode Ltd. stock has a Value Grade of B.
- DENTSPLY SIRONA Inc. stock has a Value Grade of B.
- Zimmer Biomet Holdings, Inc. stock has a Value Grade of B.
Now that you have a bit more background about each of the 4 undervalued stocks in the Health Care Equipment & Supplies industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.
We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.
A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
Additional Resources About Health Care Equipment & Supplies Stocks
Want to learn more about Health Care Equipment & Supplies stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.
- 4 Undervalued Health Care Equipment & Supplies Stocks for Monday, May 11
- Is Intuitive Surgical, Inc. (ISRG) Overvalued?
- Is Teleflex Incorporated (TFX) Stock a Good Investment?
- Which Is a Better Investment, Axogen, Inc. or NovoCure Limited Stock?
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
Yield Screen: 8.7% Compared to S&P 500
at only 6.9%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.